PERTH-BASED burns treatment developer Clinical Cell Culture Ltd, or C3, last week announced it would close its American offices and sell its CellSpray technology after completing a strategic review of its options. C3 chief executive Bob Atwill will resign from the board after 10 months in the role, to be replaced by chief financial officer Andrew Cannon, who will also retain his financial responsibilities.
